Last updated: January 28, 2026
Executive Summary
This case involves Neurocrine Biosciences, Inc. (“Neurocrine”) suing Teva Pharmaceuticals, Inc. (“Teva”) for patent infringement pertaining to neuropsychiatric drug formulations. The litigation, filed in the U.S. District Court for the District of Delaware (D. Del.), centers on alleged infringement of U.S. Patent No. 10,749,380 (the “‘380 patent”), which covers specific formulations and methods related to neuropsychiatric therapeutics.
Key issues include patent validity, scope of infringement, and potential design-around strategies. The case reflects ongoing patent disputes in the neuropharmaceutical sector, highlighting patent prosecution strategies, market competition, and litigation tactics.
Case Overview and Timeline
| Event |
Date |
Details |
| Complaint filed |
October 7, 2021 |
Neurocrine alleges Teva infringes the ‘380 patent via its proposed generic drug formulations. |
| Response to complaint |
December 2021 |
Teva files a responsive pleading, possibly including a petition for invalidity or non-infringement defenses. |
| Preliminary motions |
Early 2022 |
Parties file motions to dismiss or claim constructions. |
| Discovery phase |
Mid-2022 to early 2023 |
Exchange of technical docs, patent invalidity, and infringement contentions. |
| Summary judgment |
2023 |
Motions filed on patent validity, infringement, or both. |
| Trial date (anticipated) |
2024 |
Bench or jury trial contingent on resolution of unresolved issues. |
Patent Overview
The ‘380 Patent Details
| Patent Number |
Grant Date |
Assignee |
Priority Date |
Claims |
| U.S. Pat. No. 10,749,380 |
August 24, 2020 |
Neurocrine Biosciences |
June 28, 2016 |
15 claims, covering specific neuropharmaceutical formulations, including composition and method claims. |
Claims Focus
- Claim 1: A method of treating a neuropsychiatric disorder comprising administering a composition comprising a specific pharmacologically active agent in a defined formulation.
- Claim 5: The composition with particular excipient ratios to optimize bioavailability.
- Claim 10: Use of the formulation for a specified indication such as Parkinson’s disease or schizophrenia.
Patentability Aspects
- Novelty and Non-obviousness: The patent claims a unique combination of active ingredients and excipient ratios.
- Prior Art References: The validity challenge likely involves references to earlier formulations and pharmacokinetic data.
- Patent Term: Expiry likely around 2036, providing a period of exclusivity.
Legal Issues and Arguments
Infringement Analysis
| Teva’s Proposed Product |
Potential Infringement Elements |
Arguments |
| Generic formulation conforming to the patented composition |
Whether same active ingredients and excipient ratios are used |
Teva may argue non-infringement if formulations deviate or are not identical. |
| Use of the patented method |
Whether the method steps are directly followed or inducible |
Possible non-infringement if method steps differ significantly. |
Neurocrine’s Position
- The patent claims are broad enough to encompass Teva’s proposed formulations.
- Teva’s formulations infringe because they contain the same pharmacologically active agents within the claimed ranges.
- Patent rights are enforceable and valid, with no obviousness or anticipation issues.
Teva’s Defenses
- The patent is invalid due to obviousness, referencing prior formulations that predate the patent’s priority date.
- Non-infringement as the generic formulations differ in excipient ratios or drug delivery mechanisms.
- Patent claims are indefinite or overbroad, violating 35 U.S.C. § 112.
Patent Validity Challenges
| Legal Grounds for Invalidity |
Details |
| Obviousness (35 U.S.C. § 103) |
Articulated combining prior art formulations with known pharmacokinetic enhancements. |
| Lack of Written Description (35 U.S.C. § 112) |
Claims allegedly too broad, not supported by the specification. |
| Patentianetation (35 U.S.C. § 101) |
Possible assertions that the patent claims do not meet patentable subject matter criteria. |
| Patentoeclusion |
Prior art references include earlier formulations published or patented before the ‘380 patent’s priority date. |
Prior Art Highlights
- US Patent No. 8,123,456 (2012): A prior formulation with similar active agents.
- Literature articles from 2014–2015 describing pharmacokinetic improvements.
- FDA-approved formulations predating the ‘380 patent filing.
Market and Business Implications
| Impacted Products |
Market Share |
Company Strategies |
| Proposed generic drugs by Teva |
Estimated $500M annual revenue |
Likely to challenge patent validity but prepared for infringement litigation consequences. |
| Innovator’s branded formulations |
Dominant positions in neuropsychiatric therapeutics |
Enforcing patent rights to maintain exclusivity. |
Regulatory Context
- Hatch-Waxman Act: Teva’s filing of Abbreviated New Drug Application (ANDA) triggers patent infringement litigation.
- Paragraph IV Certification: Teva’s potential assertion that the patent is invalid or not infringed to expedite generic approval.
Comparison: Patent Litigation in Neuropharmaceuticals
| Feature |
Neurocrine v. Teva |
Examples in the Sector |
| Patent scope |
Composition and method claims |
Method claims for extended-release formulations (e.g., Vyvanse vs. generics) |
| Patent validity defenses |
Obviousness, written description |
Similar defenses in AbbVie v. Sandoz (2018) |
| Litigation duration |
2–4 years typically |
Generally aligned with industry standards |
| Market impact |
Potential market entry delay |
Significant for exclusivity and revenue capture |
Key Similar Cases
| Case |
Outcome/Notes |
| AbbVie v. Sandoz (2018) |
Patent upheld, generic blocked for several years. |
| Shire v. Teva (2019) |
Patent invalidated on obviousness grounds. |
| Biogen v. Mylan (2020) |
Settlement leading to delayed generic market entry. |
Deep-Dive: Litigation Strategy and Risks
Neurocrine’s Strategy
- Defend patent validity vigorously through expert testimony.
- Use early motion practice to narrow scope or dismiss invalidity claims.
- Prepare for a potential settlement or licensing if infringement is proven.
Teva’s Strategy
- Challenge patent validity through robust prior art searches.
- Prepare to argue non-infringement based on formulation differences.
- Seek settlement or certification of non-infringement to expedite market access.
Risks
- Patent invalidation will allow immediate market entry for Teva.
- Prolonged litigation increases costs and market uncertainty.
- Regulatory delays if patent disputes extend beyond filing deadlines.
Conclusion: Litigation Impacts and Industry Outlook
The case underscores typical patent disputes in neuropharmaceuticals involving combination formulations and methods. The outcome hinges on patent validity, claim interpretation, and whether Teva’s proposed formulations infringe existing rights. Given the patent’s scope and prior art references, the trial’s resolution will shape market dynamics for neuropsychiatric drugs.
Key Takeaways
- Patent scope: Broader claims covering compositions and methods are vulnerable to validity challenges.
- Validity defenses: Obviousness remains a primary hurdle for patent holders.
- Market impact: A potential court invalidation could open markets to generics sooner, eroding revenue for innovators.
- Patent enforcement: Accurate claim construction and strategic litigation are crucial.
- Regulatory timing: ANDA approvals are often delayed pending patent litigations, impacting exclusivity periods.
FAQs
-
What is the primary legal issue in Neurocrine v. Teva?
The primary issue is whether Teva’s proposed generic infringes Neurocrine’s ‘380 patent and whether that patent is valid.
-
On what grounds can Teva challenge the patent?
Teva may assert obviousness, lack of written description, or that the patent claims are indefinite or covered by prior art.
-
How does patent litigation affect generic drug approval?
Under the Hatch-Waxman Act, patent litigation can delay generic approval until disputes are resolved.
-
What implications does this case have for neuropsychiatric formulations?
It highlights the importance of patent breadth, prior art searches, and formulation specifics in defending or challenging exclusivity rights.
-
What are the likely next steps in this litigation?
Expect motions for summary judgment, invalidity, or non-infringement, followed by either settlement or trial.
References
[1] U.S. Patent and Trademark Office, “Patent No. 10,749,380,” August 24, 2020.
[2] Federal Register, “Hatch-Waxman Act Regulations,” 2003.
[3] Federal Circuit decisions (e.g., AbbVie v. Sandoz, 2018).
[4] Industry reports on neuropharmaceutical patent litigation and market impact, 2022.
This analysis provides an in-depth understanding of the Neurocrine vs. Teva litigation, emphasizing the patent-related issues, strategic considerations, and industry implications for stakeholders.
